Cost-saving analysis of screening colonoscopy in Germany.

Cost-saving analysis of screening colonoscopy in Germany. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cost-saving analysis of screening colonoscopy in Germany. Abstract Text:

A Sieg,H Brenner,A Sieg,H Brenner,

BACKGROUND: Screening colonoscopy was introduced into the National Cancer Prevention Program in Germany in 2002. We have explored costs and savings of screening and surveillance colonoscopy to investigate whether the induced savings may compensate for the costs of screening. METHODS: The study design was a model calculation based on data of a large-scale documentation of screening colonoscopy. The costs and savings of screening colonoscopy were evaluated over a defined period of 10 years. Basic data about findings, adverse effects and costs of screening colonoscopy were obtained from a large-scale online registry of 109 989 procedures and from the actual payments of procedures in Germany. Plausible baseline parameter values of the characteristics of screening and surveillance colonoscopy, of adenoma progression and recurrence, and of costs for diagnosis and treatment of colorectal cancer were based on available data. The impact of major model assumptions was evaluated by sensitivity analyses. RESULTS: A programme based on one-time screening colonoscopy could result in net savings over a period of 10 years in Germany due to avoidance of cancer treatment costs compensating for the costs of screening, surveillance and adverse effects. Average net savings from euro 121 to euro 623 per screenee could be achieved according to our model assuming different progression and recurrence rates of adenomas and carcinoma costs from euro 21 820 to euro 40 000. LIMITATIONS: For some major model parameters assumptions had to be derived from the literature. CONCLUSIONS: This analysis based on empirical data from the nationwide screening colonoscopy programme in Germany suggests net savings resulting from colorectal cancer prevention that compensate for the costs of screening and surveillance.

Cost-saving analysis of screening colonoscopy in Germany. Publishing Authors By Initials

A Sieg,H Brenner,A Sieg,H Brenner,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cost-saving analysis of screening colonoscopy in Germany. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Zeitschrift für Gastroenterologie

VOLUME: 45

Page Numbers: 945-51

Journal Abbreviation:

ISSN: 0044-2771

DAY: 17

MONTH: Sep

YEAR: 2007

Cost-saving analysis of screening colonoscopy in Germany. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 33370

Cost-saving analysis of screening colonoscopy in Germany. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cost-saving analysis of screening colonoscopy in Germany. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cost-saving analysis of screening colonoscopy in Germany.

AFFILIATION: Praxis für Gastroenterologie, Universität Heidelberg, Heidelberg, Germany. dr.andreas.sieg@t-online.de

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Z Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cost-saving analysis of screening colonoscopy in Germany Related Publications

• Adolescents as victims of familial violence: a hospital based surveillance.
• An S6 mutation in BK channels reveals beta1 subunit effects on intrinsic and voltage-dependent gating.
• Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception.
• BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells.
• Cadherin-11 in synovial lining formation and pathology in arthritis.
• Cost-saving analysis of screening colonoscopy in Germany.
• Differential role of I kappa B kinase 1 and 2 in primary rat hepatocytes.
• Effect of insulin on the oxidative desaturation ofa-linolenic, oleic and palmitic acids.
• Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany.
• Fifth Annual ISHAGE Meeting - Oslo 1999.
• Haptic search with finger movements: using more fingers does not necessarily reduce search times.
• Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.
• Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+.
• Non-invasive in vivo diffuse optical spectroscopy monitoring of cyanide poisoning in a rabbit model.
• Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
• Protein molecular function prediction by Bayesian phylogenomics.
• Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks.
• Relation between neural response telemetry thresholds, T- and C-levels, and loudness judgments in 12 adult nucleus 24 cochlear implant recipients.
• Relative incorporation of linoleic and arachidonic acid in phospholipids and triglycerides of different rat tissues.
• Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links.
• Systemic mediators induce fibrogenic effects in normal liver after partial bile duct ligation.
• Testing the stand-alone microbeam at Columbia University.
• The continuing contribution of gene marking to cell and gene therapy.
• The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells.
• The more eyes, the better to see? From double to quadruple reading of screening mammograms.
• The phosphatidyl ethanolamine ofPseudomonas aeruginosa grown in hexadecane.
• Timely disclosure of progress in childhood cancer survival by 'period' analysis in the Automated Childhood Cancer Information System.
• Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?
• Update on the pfam5000 strategy for selection of structural genomics targets.
• Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts.